|
1
|
Kemal Y, Teker F, Demirag G and Yucel I:
Primary testicular lymphoma: A single centre experience. Exp Oncol.
37:223–226. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vitolo U, Ferreri AJ and Zucca E: Primary
testicular lymphoma. Crit Rev Oncol Hematol. 65:183–189. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Møller MB, d'Amore F and Christensen BE:
Testicular lymphoma: a population-based study of incidence,
clinicopathological correlations and prognosis The Danish Lymphoma
Study Group, LYFO. Eur J Cancer 30A. 1760–1764. 1994. View Article : Google Scholar
|
|
4
|
Zucca E, Conconi A, Mughal TI, Sarris AH,
Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, et
al: Patterns of outcome and prognostic factors in primary
large-cell lymphoma of the testis in a survey by the International
Extranodal Lymphoma Study Group. J Clin Oncol. 21:20–27. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong Y, Sun Q and Zhang X: PD-1 and its
ligands are important immune checkpoints in cancer. Oncotarget.
8:2171–2186. 2017.PubMed/NCBI
|
|
6
|
Goodman A, Patel SP and Kurzrock R:
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev
Clin Oncol. 14:203–220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen BJ, Chapuy B, Ouyang J, Sun HH,
Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA and Rodig
SJ: PD-L1 expression is characteristic of a subset of aggressive
B-cell lymphomas and virus-associated malignancies. Clin Cancer
Res. 19:3462–3473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Francisco LM, Sage PT and Sharpe AH: The
PD-1 pathway in tolerance and autoimmunity. Immunol Rev.
236:219–242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bachy E and Coiffier B: Anti-PD1 antibody:
A new approach to treatment of lymphomas. Lancet Oncol. 15:7–8.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: From immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheah CY, Wirth A and Seymour JF: Primary
testicular lymphoma. Blood. 123:486–493. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Merryman RW, Armand P, Wright KT and Rodig
SJ: Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood
Adv. 1:2643–2654. 2017.PubMed/NCBI
|
|
16
|
Menter T, Ernst M, Drachneris J, Dirnhofer
S, Barghorn A, Went P and Tzankov A: Phenotype profiling of primary
testicular diffuse large B-cell lymphomas. Hematol Oncol. 32:72–81.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kiyasu J, Miyoshi H, Hirata A, Arakawa F,
Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, et al:
Expression of programmed cell death ligand 1 is associated with
poor overall survival in patients with diffuse large B-cell
lymphoma. Blood. 126:2193–2201. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu LY, Xu XL, Rao HL, Chen J, Lai RC,
Huang HQ, Jiang WQ, Lin TY, Xia ZJ and Cai QQ: Expression and
clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse
large B cell lymphoma: A retrospective study. Chin J Cancer.
36:942017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gascoyne RD, Adomat SA, Krajewski S,
Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P,
Coldman AJ, Reed JC and Connors JM: Prognostic significance of
Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse
aggressive non-Hodgkin's lymphoma. Blood. 90:244–251.
1997.PubMed/NCBI
|
|
21
|
Ishii H, Azuma K, Kawahara A, Yamada K,
Imamura Y, Tokito T, Kinoshita T, Kage M and Hoshino T:
Significance of programmed cell death-ligand 1 expression and its
association with survival in patients with small cell lung cancer.
J Thorac Oncol. 10:426–430. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang B, Yu W, Feng X, Zhao Z, Fan Y, Meng
Y, Hu S, Cui Y, He Q, Zhang H, et al: Prognostic significance of
PD-L1 expression on tumor cells and tumor-infiltrating mononuclear
cells in upper tract urothelial carcinoma. Med Oncol. 34:942017.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Georgiou K, Chen L, Berglund M, Ren W, de
Miranda NF, Lisboa S, Fangazio M, Zhu S, Hou Y, Wu K, et al:
Genetic basis of PD-L1 overexpression in diffuse large B-cell
lymphomas. Blood. 127:3026–3034. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Andorsky DJ, Yamada RE, Said J, Pinkus GS,
Betting DJ and Timmerman JM: Programmed death ligand 1 is expressed
by non-hodgkin lymphomas and inhibits the activity of
tumor-associated T cells. Clin Cancer Res. 17:4232–4244. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kwon D, Kim S, Kim PJ, Go H, Nam SJ, Paik
JH, Kim YA, Kim TM, Heo DS, Kim CW and Jeon YK: Clinicopathological
analysis of programmed cell death-1 and programmed cell
death-ligand 1 expression in the tumor microenvironments of diffuse
large B-cell lymphomas. Histopathology. 68:1079–1089. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xu-Monette ZY, Zhou J and Young KH: PD-1
expression and clinical PD-1 blockade in B-cell lymphomas. Blood.
131:68–83. 2018.PubMed/NCBI
|
|
27
|
Pollari M, Brück O, Pellinen T, Vähämurto
P, Karjalainen-Lindsberg ML, Mannisto S, Kallioniemi O,
Kellokumpu-Lehtinen PL, Mustjoki S, Leivonen SK and Leppä S: PD-L1+
tumor-associated macrophages and PD-1+ tumor infiltrating
lymphocytes predict survival in primary testicular lymphoma.
Haematologica. 103:1908–1914. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xing W, Dresser K, Zhang R, Evens AM, Yu
H, Woda BA and Chen BJ: PD-L1 expression in EBV-negative diffuse
large B-cell lymphoma: Clinicopathologic features and prognostic
implications. Oncotarget. 7:59976–59986. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wherry EJ and Kurachi M: Molecular and
cellular insights into T cell exhaustion. Nat Rev Immunol.
15:486–499. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pauken KE and Wherry EJ: Overcoming T cell
exhaustion in infection and cancer. Trends Immunol. 36:265–276.
2015. View Article : Google Scholar : PubMed/NCBI
|
